The funding will also allow ReCode to advance its PCD and CF programs into the clinic, and further develop its genetic medicine delivery platform to deliver additional treatments—from gene correction modalities and small interfering RNA (siRNA) therapies—to a wider range of target cell types both predictably and programmable. The financing will also enable ReCode’s planned expansion to its own 30,000-square-foot facility in Menlo Park, CA . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post SORTing It Out: ReCode Expands Beyond Respiratory Disorders appeared first on GEN – Genetic Engineering and Biotechnology News.
